Deutsche Bank Aktiengesellschaft Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold

Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research report issued on Monday, Marketbeat Ratings reports.

NVO has been the subject of several other research reports. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Six analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Stock Down 2.5%

NYSE:NVO opened at $38.64 on Monday. Novo Nordisk A/S has a one year low of $38.36 and a one year high of $93.80. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market cap of $172.52 billion, a PE ratio of 11.13 and a beta of 0.67. The firm’s 50 day simple moving average is $53.35 and its 200 day simple moving average is $53.14.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several large investors have recently bought and sold shares of NVO. Franklin Resources Inc. raised its holdings in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the last quarter. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares during the last quarter. Boston Partners bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after acquiring an additional 4,302,126 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Phase‑2 China trial: a joint Novo program (UBT251, a triple GLP‑1/GIP/glucagon agonist) reported up to ~19.7% mean weight loss at 24 weeks with a tolerable safety profile — a constructive signal for long‑term pipeline diversification beyond semaglutide. UBT251 Phase 2 China results
• Neutral Sentiment: Some investors and bullish analysts argue the market is overreacting to a single head‑to‑head miss and point to continued Wegovy/Ozempic international growth and upcoming oral options as offsetting factors. Seeking Alpha perspective
• Negative Sentiment: REDEFINE‑4 Phase‑3 miss: CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in an open‑label head‑to‑head, raising doubts about Novo’s ability to defend obesity market share against Lilly’s lead. This clinical setback is the primary catalyst for the recent sell‑off. CagriSema trial coverage
• Negative Sentiment: Price cuts: Novo announced plans to reduce U.S. list prices for Wegovy and Ozempic (up to ~50%, with headline pricing around $675/month starting Jan 2027), a move intended to improve access but likely to pressure list‑price revenue and margins. Price cut report
• Negative Sentiment: Analyst reactions and downgrades: multiple banks trimmed ratings/targets after the trial news, and coverage turned more cautious — amplifying selling pressure and repricing expectations for growth. Analyst downgrades coverage
• Negative Sentiment: Legal/investor scrutiny: law‑firm notices and investor inquiries have appeared following the clinical disclosure, representing an added reputational and potential financial overhang. Investor investigation notice

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.